Optimal Pharmacological Treatment In Patients With Heart Failure. Analysis Of The Colombian Heart Failure Registry (RECOLFACA)

• Published in: Journal of cardiac failure 2024-01, Vol.30 (1), p.175-175
• Main Authors: Gomez-Mesa, Juan, Marín, Israel E., Soria, Israel O. Marín, de Leon, Juán D. López Ponce, Escalante, Manuela, Giraldo, Clara I. Saldarriaga, Echeverria, Luis E., Toquica, Alex Rivera, Luna, Paula, Quintero, Sebastian Campbell, Rodríguez, Lisbeth N. Morales, Silgado, Gustavo Moreno, Palau, Ricardo Gómez, Madariaga, Juan C. Ortega, Estupiñan, Juan F. Carvajal, Yepes, Viviana Quintero
• Format: Article
• Language: English
• ISSN: 1071-9164; 1532-8414
• DOI: 10.1016/j.cardfail.2023.10.142

The four pillars for treatment of heart failure with reduced ejection fraction (HFrEF) patients include angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin-receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), beta-blocker (BB), mineralocorticoid receptor antagonist (MRA) and sodium-glucose cotransporter-2 inhibitor (SGLT2i), unless contraindicated or not tolerated. They should be started or up titrated to maximally tolerated doses recommended in current guidelines. Despite proven benefits and strong guideline recommendations, their use and dosing in routine clinical practice have traditionally fallen below the levels achieved in clinical trials. This analysis seeks to establish medication use and optimal dosage according to the clinical practice guidelines in HFrEF patients included in the RECOLFACA registry during recruitment and after six-month follow-up. Factors that limit its use could be identified in subsequent analysis. The RECOLFACA registry was performed between 2017 and 2019. A descriptive analysis is performed considering the medication used in HFrEF patients (ACE-I/ARB/ARNI, BB, and/or MRA) and their dosage (